Comparative Pharmacology
Head-to-head clinical analysis: HETLIOZ LQ versus ROZEREM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HETLIOZ LQ versus ROZEREM.
HETLIOZ LQ vs ROZEREM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Melatonin receptor agonist; selectively binds to and activates MT1 and MT2 receptors in the suprachiasmatic nucleus, regulating circadian rhythms and promoting sleep.
Selective melatonin receptor agonist with high affinity for MT1 and MT2 receptors in the suprachiasmatic nucleus; modulates circadian rhythm and sleep-wake cycle.
20 mg orally once daily at bedtime, taken within 30 minutes of bedtime with or without food. For delayed sleep-wake phase disorder: 0.5 mg/kg (up to 20 mg) once daily at bedtime.
8 mg orally once daily, 30 minutes before bedtime, not to exceed 8 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2.0 hours; clinical context: dosing at bedtime aligns with short half-life to avoid residual daytime sedation.
Ramelteon: 1-2.6 hours. Active metabolite M-II: 2-5 hours. Clinical context: Short half-life supports use for sleep initiation without significant next-day residual effects.
Primarily hepatic metabolism (CYP1A2, CYP3A4) with renal excretion of metabolites; unchanged tasimelteon in urine <1%; fecal excretion accounts for approximately 80% of total clearance.
Primarily renal (about 84% of total clearance), with approximately 70-80% of an oral dose excreted in urine as glucuronide conjugates of ramelteon and its active metabolite M-II. Fecal excretion accounts for about 4%.
Category C
Category C
Melatonin Receptor Agonist
Melatonin Receptor Agonist